Uniswap co-founder unveils autocompounding liquidity technology design, says it will be added to Uniswap’s roadmap.

European asset management firm 21shares has launched physically backed Zcash ETP and Ether.fi ETP on Euronext’s Paris and Amsterdam markets, tracking ZEC and ETHFI respectively. Investors can gain exposure to these assets via brokerage accounts without directly holding the underlying tokens. ETHFI is the governance and utility token of decentralized finance protocol Ether.fi. Both ETPs carry an annual management fee of 2.5%. (Cointelegraph)

Beating AI News Flash: Anthropic’s Claude Opus 5.5 is now available on all platforms, including Amazon Web Services (AWS), Google Cloud, and Microsoft Azure.

Fitch Ratings’ latest report has raised its 2027 Brent crude oil price forecast to $70 per barrel. The agency also increased its natural gas price assumption for the Netherlands’ Title Transfer Facility (TTF) amid disruptions to liquefied natural gas (LNG) shipments through the Strait of Hormuz. The report noted that Brent oil prices are projected to decline once the capacity of Saudi Arabia’s East-West oil pipeline is restored.

According to market sources, Apple Inc. has been developing a screenless device for several months. The tech giant is working on a new fitness tracker designed to compete with products from Whoop and Oura. However, Apple has not yet finalized a decision on whether to release the screenless tracker.

Viking Therapeutics Inc. shares rose sharply after the company announced positive results from a small exploratory study of its dual-target injectable obesity drug, which helped patients achieve weight loss and maintain the effect even when dosing frequency was reduced. The company drew conclusions based on data from the study’s extended patient cohort. The research was originally designed to determine the optimal dose of the drug, which regulates weight through two distinct pathways. The results are a major boost for Viking, which had faced setbacks in prior trials. The company said patients on a moderate weekly dose in the main trial phase saw the best outcomes, shedding up to 19% of their body weight over roughly five months. A 13-patient "exploratory" group continued on a slightly lower dose for an additional three months, achieving 22% weight loss with no plateau observed. Viking noted that when patients switched to a less frequent dosing regimen (once or twice monthly), some were able to maintain 90% to 97% of their weight loss. Side effects were mostly mild and eased over time, with only one patient discontinuing treatment due to adverse events. During low-frequency maintenance dosing, gastrointestinal side effects were comparable to those in the placebo group. Viking’s stock jumped as much as 36.6% during New York trading, marking its largest intraday gain since July 2024, before paring some of those gains.

According to market data from BIT (bit.com), the declines of major US bank stocks have widened: JPMorgan Chase fell 4.1%, Bank of America dropped 3.1%, Wells Fargo declined 4.2%, Citigroup fell 3.2%, Goldman Sachs dropped 1.9%, and Morgan Stanley declined 3.6%.